Intervention

Adjuvant chemotherapy

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting2

Common conditions6

Lead sponsors shown6

Clinical trials

6 shown

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine TherapyNCT06953882 · 2025-07-09

OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating LymphocytesNCT06476119 · 2025-04-15

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1NCT07450183 · 2027-01-01

NOT_YET_RECRUITING

Locoregional Recurrence After Neoadjuvant Versus Adjuvant ChemotherapyNCT06299930 · 2022-04-22

Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural MesotheliomaNCT02662504 · 2016-01-16

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast CancerNCT00675259 · 2008-07-01

Common conditions

Breast Cancer2 Breast Cancer Stage I1 HER2 Negative Breast Cancer1 Lung Cancer (NSCLC)1 Malignant Pleural Mesothelioma1 Triple Negative Breast Cancer (TNBC)1

Leading sponsors

Henry Ford Health System1 Ohio State University Comprehensive Cancer Center1 Seoul National University Hospital1 The Netherlands Cancer Institute1 University Hospital, Lille1 Yale University1

Trial status mix

COMPLETED3

RECRUITING2

NOT_YET_RECRUITING1

Phase mix

PHASE24

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.